Customized ablations following IOL implantation = spectacle independence

Article

Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence.

Following enhancement with IntraLase bioptics, nearly all patients with high preoperative astigmatism can achieve spectacle independence, according to Michael Knorz from the University Hospital, Mannheim, Germany.

Dr Knorz bilaterally implanted multifocal IOLs (Tecnis aspheric MF or ReZoom; AMO) into 14 patients with hyperopia and astigmatism of more than 2 D. A femtosecond-laser flap (IntraLase FS-60) of 100 microns and 9 mm was created immediately prior to lens surgery without lifting it. In eyes implanted with the Tecnis lens, a wavefront-guided ablation was performed, meanwhile in eyes implanted with the ReZoom lens, a standard ablation was performed with the Visx Star S4 (AMO) to fine tune the refraction.

Following implantation of the IOLs, average sphere was +0.85 and average cylinder was +1.04. After laser enhancement, sphere was +0.12 and cylinder +0.23. Higher order aberrations decreased significantly from 0.6 after IOL implantation to 0.32 after laser correction. No patient required spectacles postoperatively.

Dr Knorz believes that customized ablations following IOL implantation allows most patients to achieve spectacle independence and decreases the incidence of higher order aberrations.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.